Abstract
In this paper, a recently reported series of NPS antagonists is further expanded and biologically evaluated. The ligand efficiency and ADMET score concepts were then applied to the newly disclosed 5-phenyl-2-[2-(1-piperidinylcarbonyl) phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones, to limit the SAR exploration. Important pharmacophoric features were identified suggesting potential way forward for the identification of further developable templates.
Keywords: ADMET score, Ligand efficiency, NPS antagonists, Pharmacophore features